Aimmune enters into loan agreement with KKR; Boehringer bags rights to second RNAi drug from Dicerna
→ Having submitted its FDA application to market its peanut allergy drug in December — in effect leapfrogging rival DBV Technologies $DBVT — Aimmune Therapeutics $AIMT has entered into a $170 million loan agreement with investment firm KKR.
*sigh* When will biotech's ever learn? Don't issue debt unless you are already profitable. Things can go wrong. $SGYP is a great recent example of this, an FDA approved product that is selling (though less than expected) but they're still going bankrupt because of debt. $AIMT https://t.co/lO3glhFa1x
— Maxim Jacobs, CFA (@MaxJacobsEdison) January 4, 2019
→ Germany’s Boehringer Ingelheim has picked up rights to a second RNAi program from Dicerna. the pact is centered in finding new drugs for NASH.
→ Autoimmune disease drug developer Cabaletta Bio has closed a $50 million Series B round of financing, with participation from various investors including Deerfield. The company has raised a total of $88 million since May 2018.
→ Seattle-based Immusoft has raised $20 million to pay for a Phase I/II study of its therapy for Mucopolysaccharidosis type I. Breakout Ventures, Alexandria Venture Investments, RBV Capital, DEFTA Partners, and Mesa Verde Venture Partners contributed cash.